| Home : Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival |
|
Mar 15
2021 |
Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival |
|
TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy Trial enrolled patients with advanced cervical cancer... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/phase-3-trial-of-libtayo-cemiplimab-monotherapy-in-advanced-cervical-cancer-stopped-early-for-positive-result-on-overall-survival-301246954.html |
| |
|
Related News
|
» Nippon Express Launches Halal-certified Domestic Air Cargo Transport Service
» NetDragon to Launch E-Resource Platform for Global Teachers in Joint Project with UNESCO IITE
|
